Inj tezepelumab-ekko, 1mg
Products billed under this code include Tezspire.
Payment limit per 1 MG, by effective quarter, 4Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Tezspire.
Payment limit per 1 MG, by effective quarter, 4Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Tezspire | Amgen Inc | 55513-0112-01 | 210 | $3,746.19 |
| Tezspire | Amgen Inc | 55513-0123-01 | 210 | $3,746.19 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $17.839 | −$0.081 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted September 17, 2026 |
| 3Q26 | $17.92 | +$0.337 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted September 15, 2026 |
| 2Q26 | $17.583 | −$0.239 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted September 15, 2026 |
| 1Q26 | $17.822 | −$0.187 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted September 15, 2026 |
| 4Q25 | $18.009 | −$0.292 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted September 8, 2026 |
| 3Q25 | $18.301 | +$0.534 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted March 10, 2026 |
| 2Q25 | $17.767 | −$0.388 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted March 10, 2026 |
| 1Q25 | $18.155 | +$0.046 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted December 19, 2025 |
| 4Q24 | $18.109 | −$0.13 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted June 11, 2025 |
| 3Q24 | $18.239 | +$0.44 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted June 11, 2025 |
| 2Q24 | $17.799 | −$0.788 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted March 11, 2025 |
| 1Q24 | $18.587 | +$0.007 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted December 19, 2024 |
| 4Q23 | $18.58 | −$0.149 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted October 10, 2024 |
| 3Q23 | $18.729 | +$0.926 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted June 5, 2024 |
| 2Q23 | $17.803 | −$0.073 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted February 23, 2024 |
| 1Q23 | $17.876 | −$0.132 | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted December 6, 2023 |
| 4Q22 | $18.008 | – | 1 MG | Inj tezepelumab-ekko, 1mg | v1, posted June 22, 2023 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.